About Crizanlizumab
            
            Class: | Monoclonal antibody (selective P-selectin inhibitor)  
Use: | Treatment of sickle cell disease to reduce the frequency of vaso-occlusive crises  
Adult dose: | 5 mg/kg administered as an intravenous infusion every 2 weeks; may be increased to 7.5 mg/kg based on clinical response  
Pediatric dose: | 5 mg/kg administered as an intravenous infusion every 2 weeks for patients aged 16 years and older; safety and efficacy in patients under 16 years have not been established  
Side effects: | 
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (selective P-selectin inhibitor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of sickle cell disease to reduce the frequency of vaso-occlusive crises
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light; may be stored at room temperature (up to 25°C or 77°F) for up to 24 hours before use
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Novartis Pharmaceuticals Corporation, U.S.A
                    
                    
                    Package Size
                    1 Glass Vial (10 mg/ml)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 7163.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        5 mg/kg administered as an intravenous infusion every 2 weeks; may be increased to 7.5 mg/kg based on clinical response
                    
                    
                        Pediatric Dose
                    
                    
                        5 mg/kg administered as an intravenous infusion every 2 weeks for patients aged 16 years and older; safety and efficacy in patients under 16 years have not been established
                    
                 
                
                
                    
                        Side Effects
                    
                    Headache, nausea, fatigue, abdominal pain, infusion-related reactions, and musculoskeletal pain
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to crizanlizumab or any component of the formulation; caution in patients with a history of severe allergic reactions
         
        
        
            
                Important Warnings
            
            Risk of infusion-related reactions; monitor patients during and after infusion; potential for increased risk of infections; not recommended for use in patients with active or serious infections
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.